{"id":29389,"date":"2025-03-16T22:15:29","date_gmt":"2025-03-16T14:15:29","guid":{"rendered":"https:\/\/flcube.com\/?p=29389"},"modified":"2025-03-16T22:15:31","modified_gmt":"2025-03-16T14:15:31","slug":"rona-therapeutics-secures-25m-pre-b-round-to-advance-sirna-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29389","title":{"rendered":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies"},"content":{"rendered":"\n

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company’s proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.<\/p>\n\n\n\n

Investor Support and Confidence<\/strong>
The round was led by Guanghua Wutong, with participation from Lilly Asia Ventures, LongRiver Investments, BioTrack Capital, and other new and existing investors. This support underscores the confidence in Rona Therapeutics’ innovation in the nucleic acid drug space.<\/p>\n\n\n\n

Funding Utilization<\/strong>
Proceeds from this financing will be used to advance Rona Therapeutics’ clinical studies, deepen the research and development of extrahepatic systemic drug delivery platform, and enhance its large-scale production capabilities. The company has made significant progress in clinical pipeline advancement and preclinical research, validating its platform’s technical advantages and clinical potential.<\/p>\n\n\n\n

Strategic Vision<\/strong>
Since its founding in 2021, Rona Therapeutics has established itself as a leader in siRNA therapeutics through its modular and programmable delivery and chemical modification platforms. The company is committed to addressing complex diseases such as hypercholesterolemia and hypertriglyceridemia. This Pre-B financing will further solidify Rona Therapeutics’ position in the global oligonucleotide drug market.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B…<\/p>\n","protected":false},"author":1,"featured_media":29390,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[20,498],"class_list":["post-29389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finance","tag-rona-therapeutics"],"yoast_head":"\nRona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company's proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29389\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company's proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29389\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-16T14:15:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-16T14:15:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies\",\"datePublished\":\"2025-03-16T14:15:29+00:00\",\"dateModified\":\"2025-03-16T14:15:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1602-png.avif\",\"keywords\":[\"Finance\",\"Rona Therapeutics\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29389#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29389\",\"name\":\"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1602-png.avif\",\"datePublished\":\"2025-03-16T14:15:29+00:00\",\"dateModified\":\"2025-03-16T14:15:31+00:00\",\"description\":\"Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company's proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29389\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1602-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1602-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29389#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies - Insight, China's Pharmaceutical Industry","description":"Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company's proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29389","og_locale":"en_US","og_type":"article","og_title":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies","og_description":"Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company's proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.","og_url":"https:\/\/flcube.com\/?p=29389","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-16T14:15:29+00:00","article_modified_time":"2025-03-16T14:15:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29389#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29389"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies","datePublished":"2025-03-16T14:15:29+00:00","dateModified":"2025-03-16T14:15:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29389"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29389#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif","keywords":["Finance","Rona Therapeutics"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29389#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29389","url":"https:\/\/flcube.com\/?p=29389","name":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29389#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29389#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif","datePublished":"2025-03-16T14:15:29+00:00","dateModified":"2025-03-16T14:15:31+00:00","description":"Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company's proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29389#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29389"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29389#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif","width":1080,"height":608,"caption":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29389#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1602-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29389"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29389\/revisions"}],"predecessor-version":[{"id":29391,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29389\/revisions\/29391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29390"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}